TrialCancer communications (London, England)2023

A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations.

Pingli Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.